Skip to main content
SpringerLink
Log in

Tumor Antigens and Tumor Antigen Discovery

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Gromet, M.A., W.L. Epstein, and M.S. Blois. 1978. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 42:2282–2292.

    Article  PubMed  CAS  Google Scholar 

  2. Hellstrom, K.E., and I. Hellstrom. 1969. Cellular immunity against tumor antigens. Adv Cancer Res 12:167–223.

    PubMed  CAS  Google Scholar 

  3. Vanky, F., and E. Klein. 1982. Specificity of auto-tumor cytotoxicity exerted by fresh, activated and propagated human T lymphocytes. Int J Cancer 29:547–553.

    Article  PubMed  CAS  Google Scholar 

  4. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, L. Rivoltini, S.L. Topalian, T. Miki, and S.A. Rosenberg. 1994a. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 91:3515–3519.

    Article  PubMed  CAS  Google Scholar 

  5. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643–1647.

    Article  PubMed  Google Scholar 

  6. Renkvist, N., C. Castelli, P.F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15.

    Article  PubMed  CAS  Google Scholar 

  7. Brandle, D., J. Bilsborough, T. Rulicke, C. Uyttenhove, T. Boon, and B.J. Van den Eynde. 1998. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection. Eur J Immunol 28:4010–4019.

    Article  PubMed  CAS  Google Scholar 

  8. Ramarathinam, L., S. Sarma, M. Maric, M. Zhao, G. Yang, L. Chen, and Y. Liu. 1995. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. J Immunol 155:5323–5329.

    PubMed  CAS  Google Scholar 

  9. Rosato, A., A. Zambon, G. Milan, V. Ciminale, D.M. D’Agostino, B. Macino, P. Zanovello, and D. Collavo. 1997. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther 8:1451–1458.

    PubMed  CAS  Google Scholar 

  10. Greenberg, P.D., M.A. Cheever, and A. Fefer. 1981. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes. J Exp Med 154:952–963.

    Article  PubMed  CAS  Google Scholar 

  11. Rosenberg, S.A., B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, et al. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319:1676–1680.

    Article  PubMed  CAS  Google Scholar 

  12. De Plaen, E., C. Lurquin, A. Van Pel, B. Mariame, J.P. Szikora, T. Wolfel, C. Sibille, P. Chomez, and T. Boon. 1988. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci U S A 85:2274–2278.

    Article  PubMed  Google Scholar 

  13. Gilboa, E. 1999. The makings of a tumor rejection antigen. Immunity 11:263–270.

    Article  PubMed  CAS  Google Scholar 

  14. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601–624.

    PubMed  CAS  Google Scholar 

  15. Garrido, F., F. Ruiz-Cabello, T. Cabrera, J.J. Perez-Villar, M. Lopez-Botet, M. Duggan-Keen, and P.L. Stern. 1997. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89–95.

    Article  PubMed  CAS  Google Scholar 

  16. Hicklin, D.J., F.M. Marincola, and S. Ferrone, 1999. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178–186.

    Article  PubMed  CAS  Google Scholar 

  17. Cohen, P.A., L. Peng, G.E. Plautz, J.A. Kim, D.E. Kim, and S. Shu. 2000. CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 20:17–56.

    PubMed  CAS  Google Scholar 

  18. Toes, R.E., F. Ossendorp, R. Offringa, and C.J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753–756.

    Article  PubMed  CAS  Google Scholar 

  19. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4( +) T cells in the antitumor immune response. J Exp Med 188:2357–2368.

    Article  PubMed  CAS  Google Scholar 

  20. Romerdahl, C.A., and M.L. Kripke. 1988. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res 48:2325–2328.

    PubMed  CAS  Google Scholar 

  21. Schild, H.J., B. Kyewski, P. Von Hoegen, and V. Schirrmacher. 1987. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor. Eur J Immunol 17:1863–1866.

    Article  PubMed  CAS  Google Scholar 

  22. Frasca, L., C. Piazza, and E. Piccolella. 1998. CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells. Crit Rev Immunol 18:569–594.

    PubMed  CAS  Google Scholar 

  23. Kao, H., J.A. Marto, T.K. Hoffmann, J. Shabanowitz, S.D. Finkelstein, T.L. Whiteside, D.F. Hunt, and O.J. Finn. 2001b. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313–1323.

    Article  PubMed  CAS  Google Scholar 

  24. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J.Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493–497.

    Article  PubMed  CAS  Google Scholar 

  25. Becker, J.C., C. Czerny, and E.B. Brocker. 1994. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol 6:1605–1612.

    Article  PubMed  CAS  Google Scholar 

  26. Thurner, B., I. Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, P. von den Driesch. et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669–1678.

    Article  PubMed  CAS  Google Scholar 

  27. Jager, E., M. Ringhoffer, J. Karbach, M. Arand, F. Oesch, and A. Knuth. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66:470–476.

    Article  PubMed  CAS  Google Scholar 

  28. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L.A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833–841.

    Article  PubMed  CAS  Google Scholar 

  29. Touloukian, C.E., W.W. Leitner, R.E. Schnur, P.F. Robbins, Y. Li, S. Southwood, A. Sette, S. A. Rosenberg, and N.P. Restifo. 2003. Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol 170:1579–1585.

    PubMed  CAS  Google Scholar 

  30. Perales, M.A., N.E. Blachere, M.E. Engelhorn, C.R. Ferrone, J. S. Gold, P.D. Gregor, G. Noffz, J.D. Wolchok, and A.N. Houghton. 2002. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 12:63–71.

    Article  PubMed  CAS  Google Scholar 

  31. Rosenberg, S.A. 1995. Cell transfer therapy: clinical applications. In Biological Therapy of Cancer, H.S.V.T. DeVita, S.A. Rosenberg, eds. Lippincott, Philadelphia: 487–506.

    Google Scholar 

  32. Rosenberg, S.A. 1996. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88:1635–1644.

    Article  PubMed  CAS  Google Scholar 

  33. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994b. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 91:6458–6462.

    Article  PubMed  CAS  Google Scholar 

  34. Robbins, P.F., M. el-Gamil, Y. Kawakami, E. Stevens, J.R. Yannelli, and S.A. Rosenberg. 1994. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124–3126.

    PubMed  CAS  Google Scholar 

  35. Wang, R.F., P.F. Robbins, Y. Kawakami, X.Q. Kang, and S.A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799–804.

    Article  PubMed  CAS  Google Scholar 

  36. Topalian, S.L., L. Rivoltini, M. Mancini, N.R. Markus, P.F. Robbins, Y. Kawakami, and S.A. Rosenberg. 1994. Human CD4+T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 91:9461–9465.

    Article  PubMed  CAS  Google Scholar 

  37. Robbins, P.F., M. el-Gamil, Y.F. Li, S.L. Topalian, L. Rivoltini, K. Sakaguchi, E. Appella, Y. Kawakami, and S.A. Rosenberg. 1995. Cloning of a new gene encoding an antigen recognized by melanomaspecific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154:5944–5950.

    PubMed  CAS  Google Scholar 

  38. Robbins, P.F., M. El-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, and S.A. Rosenberg. 1996. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185–1192.

    Article  PubMed  CAS  Google Scholar 

  39. Sahin, U., O. Tureci, and M. Pfreundschuh. 1997. Serological identification of human tumor antigens. Curr Opin Immunol 9:709–716.

    Article  PubMed  CAS  Google Scholar 

  40. Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 92:11810–11813.

    Article  PubMed  CAS  Google Scholar 

  41. Old, L.J., and Y.T. Chen. 1998. New paths in human cancer serology. J Exp Med 187:1163–1167.

    Article  PubMed  CAS  Google Scholar 

  42. Tureci, O., U. Sahin, and M. Pfreundschuh. 1997. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 3:342–349.

    Article  PubMed  CAS  Google Scholar 

  43. Tureci, O., U. Sahin, I. Schobert, M. Koslowski, H. Scmitt, H. J. Schild, F. Stenner, G. Seitz, H.G. Rammensee, and M. Pfreundschuh. 1996. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56:4766–4772.

    PubMed  CAS  Google Scholar 

  44. Chen, Y. T., M.J. Scanlan, U. Sahin, O. Tureci, A.O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L.J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94:1914–1918.

    Article  PubMed  CAS  Google Scholar 

  45. Tureci, O., U. Sahin, C. Zwick, M. Koslowski, G. Seitz, and M. Pfreundschuh. (1998). Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95:5211–5216.

    Article  PubMed  CAS  Google Scholar 

  46. Chen, Y. T., A.O. Gure, S. Tsang, E. Stockert, E. Jager, A. Knuth, and L.J. Old. 1998. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 95:6919–6923.

    Article  PubMed  CAS  Google Scholar 

  47. Boel, P., C. Wildmann, M.L. Sensi, R. Brasseur, J.C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167–175.

    Article  PubMed  CAS  Google Scholar 

  48. Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689–698.

    Article  PubMed  Google Scholar 

  49. Jager, E., Y.T. Chen, J.W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert et al. (1998). Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270.

    Article  PubMed  CAS  Google Scholar 

  50. Brass, N., D. Heckel, U. Sahin, M. Pfreundschuh, G.W. Sybrecht, and E. Meese. 1997. Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 6:33–39.

    Article  PubMed  CAS  Google Scholar 

  51. Gure, A. O., N.K. Altorki, E. Stockert, M.J. Scanlan, L.J. Old, and Y.T. Chen. 1998. Human lung cancer antigens recognized by autologous antibodies: definition of a novel cDNA derived from the tumor suppressor gene locus on chromosome 3p21.3. Cancer Res 58:1034–1041.

    PubMed  CAS  Google Scholar 

  52. Scanlan, M.J., Y.T. Chen, B. Williamson, A.O. Gure, E. Stockert, J.D. Gordan, O. Tureci, U. Sahin, M. Pfreundschuh, and L.J. Old. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 76:652–658.

    Article  PubMed  CAS  Google Scholar 

  53. Cox, A.L., J. Skipper, Y. Chen, R.A. Henderson, T.L. Darrow, J. Shabanowitz, V.H. Engelhard, D.F. Engelhard, and Jr. C.L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716–719.

    Article  PubMed  CAS  Google Scholar 

  54. Schirle, M., W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H.D. Becker, S. Stevanovic, and H.G. Rammensee. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur J Immunol 30:2216–2225.

    Article  PubMed  CAS  Google Scholar 

  55. Pieper, R., R.E. Christian, M.I. Gonzales, M.I. Nishimura, G. Gupta, R.E. Settlage, J. Shabanowitz, S.A. Rosenberg, D.F. Hunt, and S.L. Topalian. 1999. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 189:757–766.

    Article  PubMed  CAS  Google Scholar 

  56. Velculescu, V.E., L. Zhang, B. Vogelstein, and K.W. Kinzler. 1995. Serial analysis of gene expression. Science 270:484–487.

    Article  PubMed  CAS  Google Scholar 

  57. Zhang, L., W. Zhou, V.E. Velculescu, S.E. Kern, R.H. Hruban, S.R. Hamilton, B. Vogelstein, and K.W. Kinzler. 1997. Gene expression profiles in normal and cancer cells. Science 276:1268–1272.

    Article  PubMed  CAS  Google Scholar 

  58. Wang, T., D. Hopkins, C. Schmidt, S. Silva, R. Houghton, H. Takita, E. Repasky, and S.G. Reed. 2000. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene 19:1519–1528.

    Article  PubMed  CAS  Google Scholar 

  59. Wang, T., L. Fan, Y. Watanabe, P. McNeill, G.R. Fanger, D.H. Persing, and S.G. Reed. 2001. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 20:7699–7709.

    Article  PubMed  CAS  Google Scholar 

  60. Lisitsyn, N., and M. Wigler. 1993. Cloning the differences between two complex genomes. Science 259:946–951.

    Article  PubMed  CAS  Google Scholar 

  61. O’Neill, M.J., and A.H. Sinclair. 1997. Isolation of rare transcripts by representational difference analysis. Nucleic Acids Res 25:2681–2682.

    Article  PubMed  CAS  Google Scholar 

  62. Lethe, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int J Cancer 76:903–908.

    Article  PubMed  CAS  Google Scholar 

  63. Lucas, S., C. De Smet, K.C. Arden, C.S. Viars, B. Lethe, C. Lurquin, and T. Boon. 1998. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58:743–752.

    PubMed  CAS  Google Scholar 

  64. Gure, A.O., E. Stockert, K.C. Arden, A.D. Boyer, C.S. Viars, M.J. Scanlan, L.J. Old, and Y.T. Chen. 2000. CT10: a new cancer-testis (CT) antigen homologous to CT7 and the MAGE family, identified by representational-difference analysis. Int J Cancer 85:726–732.

    Article  PubMed  CAS  Google Scholar 

  65. Schultze, J.L., and R.H. Vonderheide. 2001. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol 22:516–523.

    Article  PubMed  CAS  Google Scholar 

  66. Nussbaum, A.K., C. Kuttler, S. Tenzer, and H. Schild. 2003. Using the World Wide Web for predicting CTL epitopes. Curr Opin Immunol 15:69–74.

    Article  PubMed  CAS  Google Scholar 

  67. Parker, K.C., M.A. Bednarek, and J.E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175.

    PubMed  CAS  Google Scholar 

  68. Rammensee, H., J. Bachmann, N.P. Emmerich, O.A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213–219.

    Article  PubMed  CAS  Google Scholar 

  69. Kuttler, C., A.K. Nussbaum, T.P. Dick, H.G. Rammensee, H. Schild, and K.P. Hadeler. 2000. An algorithm for the prediction of proteasomal cleavages. J Mol Biol 298:417–429.

    Article  PubMed  CAS  Google Scholar 

  70. Nussbaum, A.K., C. Kuttler, K.P. Hadeler, H.G. Rammensee, and H. Schild. 2001. PAProC: a prediction algorithm for proteasomal cleavages available on the WWW. Immunogenetics 53:87–94.

    Article  PubMed  CAS  Google Scholar 

  71. Kesmir, C., A.K. Nussbaum, H. Schild, V. Detours, and S. Brunak. 2002. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 15, 287–296.

    Article  PubMed  CAS  Google Scholar 

  72. Schumacher, T.N., M.T. Heemels, J.J. Neefjes, W.M. Kast, C. J. Melief, and H.L. Ploegh. 1990. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62:563–567.

    Article  PubMed  CAS  Google Scholar 

  73. Tompkins, S.M., P.A. Rota, J.C. Moore, and P.E. Jensen. 1993. A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins. J Immunol Methods 163:209–216.

    Article  PubMed  CAS  Google Scholar 

  74. Vonderheide, R.H., W.C. Hahn, J.L. Schultze, and L.M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673–679.

    Article  PubMed  CAS  Google Scholar 

  75. Kim, N.W., M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, and J.W. Shay. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015.

    Article  PubMed  CAS  Google Scholar 

  76. Greenberg, R.A., L. Chin, A. Femino, K.H. Lee, G.J. Gottlieb, R.H. Singer, C.W. Greider, and R.A. DePinho. 1999. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97:515–525.

    Article  PubMed  CAS  Google Scholar 

  77. Hahn, W.C., C.M. Counter, A.S. Lundberg, R.L. Beijersbergen, M.W. Brooks, and R.A. Weinberg. 1999. Creation of human tumour cells with defined genetic elements. Nature 400:464–468.

    Article  PubMed  CAS  Google Scholar 

  78. Minev, B., J. Hipp, H. Firat, J.D. Schmidt, P. Langlade-Demoyen, and M. Zanetti. 2000. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A 97:4796–4801.

    Article  PubMed  CAS  Google Scholar 

  79. Scardino, A., D.A. Gross, P. Alves, J.L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L.M. Nadler, F.A. Lemonnier, et al. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900–5906.

    PubMed  CAS  Google Scholar 

  80. Vonderheide, R.H., K.S. Anderson, W.C. Hahn, M.O. Butler, J.L. Schultze, and L.M. Nadler. 2001a. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase. Clin Cancer Res 7:3343–3348.

    PubMed  CAS  Google Scholar 

  81. Vonderheide, R.H., J.L. Schultze, K.S. Anderson, B. Maecker, M.O. Butler, Z. Xia, M.J. Kuroda, M.S. von Bergwelt-Baildon, M.M. Bedor, K.M. Hoar, et al. 2001b. Equivalent induction of telomerasespecific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 61:8366–8370.

    PubMed  CAS  Google Scholar 

  82. Vonderheide, R.H. (2002). Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21:674–679.

    Article  PubMed  CAS  Google Scholar 

  83. Kessler, J.H., N.J. Beekman, S.A. Bres-Vloemans, P. Verdijk, P.A. van Veelen, A.M. Kloosterman-Joosten, D.C. Vissers, G.J. ten Bosch, M.G. Kester, A. Sijts, et al. 2001. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 193:73–88.

    Article  PubMed  CAS  Google Scholar 

  84. Noppen, C., F. Levy, L. Burri, P. Zajac, E. Remmel, C. Schaefer, U. Luscher, M. Heberer, and G.C. Spagnoli. 2000. Naturally processed and concealed HLA-A2.1-restricted epitopes from tumor-associated antigen tyrosinase-related protein-2. Int J Cancer 87:241–246.

    Article  PubMed  CAS  Google Scholar 

  85. Berger, C.L., J. Longley, D. Hanlon, M. Girardi, and R. Edelson. 2001. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann N Y Acad Sci 941:106–122.

    Article  PubMed  CAS  Google Scholar 

  86. Banchereau, J., and R.M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245–252.

    Article  PubMed  CAS  Google Scholar 

  87. Kao, H., A.A. Amoscato, P. Ciborowski, and O.J. Finn. 2001a. A new strategy for tumor antigen discovery based on in vitro priming of naive T cells with dendritic cells. Clin Cancer Res 7:773s–780s.

    PubMed  CAS  Google Scholar 

  88. Vinals, C., S. Gaulis, and T. Coche. 2001. Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy. Vaccine 19:2607–2614.

    Article  PubMed  CAS  Google Scholar 

  89. Audic, S., and J.M. Claverie. 1997. The significance of digital gene expression profiles. Genome Res 7:986–995.

    PubMed  CAS  Google Scholar 

  90. Fannon, M.R. 1996. Gene expression in normal and disease states—identification of therapeutic targets. Trends Biotechnol 14:294–298.

    Article  PubMed  CAS  Google Scholar 

  91. Hohn, H., H. Pilch, S. Gunzel, C. Neukirch, K. Freitag, A. Necker, and M.J. Maeurer. 2000. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol 74: 6632–6636.

    Article  PubMed  CAS  Google Scholar 

  92. Evans, E.M., S. Man, A.S. Evans, and L.K. Borysiewicz. 1997. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57:2943–2950.

    PubMed  CAS  Google Scholar 

  93. Murakami, M., K.J. Gurski, F.M. Marincola, J. Ackland, and M.A. Steller. (1999). Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res 59:1184–1187.

    PubMed  CAS  Google Scholar 

  94. Hohn, H., H. Pilch, S. Gunzel, C. Neukirch, C. Hilmes, A. Kaufmann, B. Seliger, and M.J. Maeurer. 1999. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 163: 5715–5722.

    PubMed  CAS  Google Scholar 

  95. Cromme, F.V., J. Airey, M.T. Heemels, H.L. Ploegh, P.J. Ploegh, P.L. Stern, C.J. Meijer, and J.M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 179:335–340.

    Article  PubMed  CAS  Google Scholar 

  96. Gottschalk, S., H.E. Heslop, and C.M. Roon. 2002. Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 84:175–201.

    PubMed  CAS  Google Scholar 

  97. Gahn, B., F. Siller-Lopez, A.D. Pirooz, E. Yvon, S. Gottschalk, R. Longnecker, M.K. Brenner, H.E. Heslop, E. Aguilar-Cordova, and C.M. Rooney. 2001. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin’s lymphoma. Int J Cancer 93:706–713.

    Article  PubMed  CAS  Google Scholar 

  98. Ranieri, E., W. Herr, A. Gambotto, W. Olson, D. Rowe, P.D. Robbins, L.S. Kierstead, S.C. Watkins, L. Gesualdo, and W.J. Storkus. 1999. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 73:10416–10425.

    PubMed  CAS  Google Scholar 

  99. Su, Z., M.V. Peluso, S.H. Raffegerst, D.J. Schendel, and M. A. Roskrow. 2001. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 31:947–958.

    Article  PubMed  CAS  Google Scholar 

  100. Khanim, F., Yao, Q. Y. Niedobitek, G. Sihota, S. Rickinson, A. B. and Young, L. S. 1996. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 88, 3491–3501.

    PubMed  CAS  Google Scholar 

  101. Khanna, R., S.R. Burrows, J. Burrows, and L.M. Poulsen. 1998. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 28:451–458.

    Article  PubMed  CAS  Google Scholar 

  102. Knecht, H., E. Bachmann, P. Brousset, K. Sandvej, D. Nadal, F. Bachmann, B.F. Odermatt, G. Delsol, and G. Pallesen. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin’s disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937–2942.

    PubMed  CAS  Google Scholar 

  103. Lee, S.P., A.T. Chan, S.T. Cheung, W.A. Thomas, D. CroomCarter, C.W. Dawson, C.H. Tsai, S.F. Leung, P.J. Johnson, and D.P. Huang. 2000. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. J Immunol 165:573–582.

    PubMed  CAS  Google Scholar 

  104. Gustafsson, A., V. Levitsky, J.Z. Zou, T. Frisan, T. Dalianis, P. Ljungman, O. Ringden, J. Winiarski, I. Ernberg, and M.G. Masucci. 2000. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814.

    PubMed  CAS  Google Scholar 

  105. Rooney, C.M., C.A. Smith, C.Y. Ng, S.K. Loftin, J.W. Sixbey, Y. Gan, D.K. Srivastava, L.C. Bowman, R.A. Krance, M.K. Brenner, and H.E. Heslop. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555.

    PubMed  CAS  Google Scholar 

  106. Gottschalk, S., C.Y. Ng, M. Perez, C.A. Smith, C. Sample, M.K. Brenner, H.E. Heslop, and C.M. Rooney. 2001. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 97:835–843.

    Article  PubMed  CAS  Google Scholar 

  107. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M., Steigerwald-Mullen, M.G. Klein, G. Kurilla, and M.G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685–688.

    Article  PubMed  CAS  Google Scholar 

  108. Bickham, K., C. Munz, M.L. Tsang, M. Larsson, J.F. Fonteneau, N. Bhardwaj, and R. Steinman. 2001. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 107:121–130.

    PubMed  CAS  Google Scholar 

  109. Munz, C., K.L. Bickham, M. Subklewe, M.L. Tsang, A. Chahroudi, M.G. Kurilla, D. Zhang, M. O’Donnell, and R.M. Steinman. 2000. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191: 1649–1660.

    Article  PubMed  CAS  Google Scholar 

  110. Chisari, F. V., and C. Ferrari. 1995. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29–60.

    Article  PubMed  CAS  Google Scholar 

  111. Couillin, I., S. Pol, M. Mancini, F. Driss, C. Brechot, P. Tiollais, and M.L. Michel. 1999. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26.

    Article  PubMed  CAS  Google Scholar 

  112. Chun, E., J. Lee, H.S. Cheong, and K.Y. Lee. 2003. Tumor eradication by hepatitis B virus x antigen-specific CD8(+) T cells in xenografted nude mice. J Immunol 170:1183–1190.

    PubMed  CAS  Google Scholar 

  113. Michel, M.L., S. Pol, C. Brechot, and P. Tiollais. 2001. Immunotherapy of chronic hepatitis B by anti HBV vaccine: from present to future. Vaccine 19:2395–2399.

    Article  PubMed  CAS  Google Scholar 

  114. Koziel, M.J., D. Dudley, N. Afdhal, Q.L. Choo, M. Houghton, R. Ralston, and B.D. Walker. 1993. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 67:7522–7532.

    PubMed  CAS  Google Scholar 

  115. Koziel, M.J., D. Dudley, N. Afdhal, A. Grakoui, C.M. Rice, Q.L. Choo, M. Houghton, and B.D. Walker. 1995. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311–2321.

    Article  PubMed  CAS  Google Scholar 

  116. Koziel, M.J., D. Dudley, J.T. Wong, J. Dienstag, M. Houghton, R. Ralston, and B.D. Walker. 1992. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 149:3339–3344.

    PubMed  CAS  Google Scholar 

  117. Ferrari, C., A. Valli, L. Galati, A. Penna, P. Scaccaglia, T. Giuberti, C. Schianchi, G. Missale, M. G. Marin, and F. Fiaccadori. 1994. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 19, 286–295.

    Article  PubMed  CAS  Google Scholar 

  118. Hoffmann, R.M., H.M. Diepolder, R. Zachoval, F.M. Zwiebel, M. C. Jung, S. Scholz, H. Nitschko, G. Riethmuller, and G.R. Pape. 1995. Mapping of immunodominant CD4 + T lymphocyte epitopes of hepatitis C virus antigens and their relevance during the course of chronic infection. Hepatology 21:632–638.

    PubMed  CAS  Google Scholar 

  119. Diepolder, H.M., R. Zachoval, R.M. Hoffmann, E.A. Wierenga, T. Santantonio, M.C. Jung, D. Eichenlaub, and G.R. Pape. 1995. Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346:1006–1007.

    Article  PubMed  CAS  Google Scholar 

  120. Avantaggiati, M.L., G. Natoli, C. Balsano, P. Chirillo, M. Artini, E. De Marzio, D. Collepardo, and M. Levrero. 1993. The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. Oncogene 8:1567–1574.

    PubMed  CAS  Google Scholar 

  121. Benn, J., and R.J. Schneider. 1995. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci U S A 92:11215–11219.

    Article  PubMed  CAS  Google Scholar 

  122. Koutsky, L.A., K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez, L.M. Chiacchierini, and K.U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651.

    Article  PubMed  CAS  Google Scholar 

  123. Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930.

    Article  PubMed  CAS  Google Scholar 

  124. Traversari, C., P. van der Bruggen, I.F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453–1457.

    Article  PubMed  CAS  Google Scholar 

  125. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J.P. Szikora et al. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35–42.

    Article  PubMed  CAS  Google Scholar 

  126. Brichard, V., A. Van Pel, T. Wolfel, C. Wolfel, E. De Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489–495.

    Article  PubMed  CAS  Google Scholar 

  127. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P.F. Robbins, A. Sette, E. Appella, and S.A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961–3968.

    PubMed  CAS  Google Scholar 

  128. Wolfel, T., M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K. H. Meyer zum Buschenfelde, and D. Beach. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281–1284.

    Article  PubMed  CAS  Google Scholar 

  129. Coulie, P.G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A 92:7976–7980.

    Article  PubMed  CAS  Google Scholar 

  130. Winter, S.F., J.D. Minna, B.E. Johnson, T. Takahashi, A.F. Gazdar, and D.P. Carbone. 1992. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52:4168–4174.

    PubMed  CAS  Google Scholar 

  131. Yanuck, M., D.P. Carbone, C.D. Pendleton, T. Tsukui, S.F. Winter, J.D. Minna, and J.A. Berzofsky. 1993. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 53:3257–3261.

    PubMed  CAS  Google Scholar 

  132. Disis, M.L., and M. A. Cheever. 1996. Oncogenic proteins as tumor antigens. Curr Opin Immunol 8:637–642.

    Article  PubMed  CAS  Google Scholar 

  133. Ikeda, H., B. Lethe, F. Lehmann, N. van Baren, J.F. Baurain, C. de Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, and P.G. Coulie. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208.

    Article  PubMed  CAS  Google Scholar 

  134. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P.G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340–347.

    Article  PubMed  CAS  Google Scholar 

  135. Shichijo, S., M. Nakao, Y. Imai, H. Takasu, M. Kawamoto, F. Niiya, D. Yang, Y. Toh, H. Yamana, and K. Itoh. 1998. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277–288.

    Article  PubMed  CAS  Google Scholar 

  136. Tilkin, A.F., R. Lubin, T. Soussi, V. Lazar, N. Janin, M.C. Mathieu, I. Lefrere, C. Carlu, M. Roy, M. Kayibanda, et al. 1995. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25:1765–1769.

    Article  PubMed  CAS  Google Scholar 

  137. Finn, O.J., K.R. Jerome, R.A. Henderson, G. Henderson, N. Henderson, J. Magarian-Blander, and S.M. Barratt-Boyes. 1995. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61–89.

    Article  PubMed  CAS  Google Scholar 

  138. Disis, M.L., and M.A. Cheever. 1998. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 18:37–45.

    PubMed  CAS  Google Scholar 

  139. Tsang, K. Y., S. Zaremba, C.A. Nieroda, M.Z. Zhu, J.M. Hamilton, and J. Schlom. 1995. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982–990.

    Article  PubMed  CAS  Google Scholar 

  140. Vlad, A.M., S. Muller, M. Cudic, H. Paulsen, L. Jr. Otvos, F.G. Hanisch, and O.J. Finn. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class IIrestricted T cells. J Exp Med 196:1435–1446.

    Article  PubMed  CAS  Google Scholar 

  141. Kim, Y.J., and A. Varki. 1997. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 14:569–576.

    Article  PubMed  CAS  Google Scholar 

  142. Sercarz, E.E. (2000). Driver clones and determinant spreading. J Autoimmun 14, 275–277.

    Article  PubMed  CAS  Google Scholar 

  143. Vanderlugt, C.L., and S.D. Miller. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:85–95.

    Article  PubMed  CAS  Google Scholar 

  144. Ribas, A., J.M. Timmerman, L.H. Butterfield, and J.S. Economou. 2003. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58–61.

    Article  PubMed  CAS  Google Scholar 

  145. Brossart, P., S. Wirths, G. Stuhler, V.L. Reichardt, L. Kanz, and W. Brugger. 2000. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108.

    PubMed  CAS  Google Scholar 

  146. Lally, K.M., S. Mocellin, G.A. Ohnmacht, M.B. Nielsen, M. Bettinotti, M.C. Panelli, V. Monsurro, and F.M. Marincola. 2001. Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 93:841–847.

    Article  PubMed  CAS  Google Scholar 

  147. Ranieri, E., L.S. Kierstead, H. Zarour, J.M. Kirkwood, M.T. Lotze, T. Whiteside, and W.J. Storkus. 2000. Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29:121–125.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pittsburgh, Pittsburgh, PA, 15261

    Daniel F. Graziano & Olivera J. Finn

Authors
  1. Daniel F. Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivera J. Finn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Graziano, D.F., Finn, O.J. (2005). Tumor Antigens and Tumor Antigen Discovery. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_4

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation